These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18325673)

  • 21. Spontaneous and deliberate creative cognition during and after psilocybin exposure.
    Mason NL; Kuypers KPC; Reckweg JT; Müller F; Tse DHY; Da Rios B; Toennes SW; Stiers P; Feilding A; Ramaekers JG
    Transl Psychiatry; 2021 Apr; 11(1):209. PubMed ID: 33833225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment.
    Burdick BV; Adinoff B
    Am J Drug Alcohol Abuse; 2013 Sep; 39(5):291-7. PubMed ID: 23968172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin.
    Carter OL; Pettigrew JD; Hasler F; Wallis GM; Liu GB; Hell D; Vollenweider FX
    Neuropsychopharmacology; 2005 Jun; 30(6):1154-62. PubMed ID: 15688092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability.
    Carhart-Harris RL; Williams TM; Sessa B; Tyacke RJ; Rich AS; Feilding A; Nutt DJ
    J Psychopharmacol; 2011 Nov; 25(11):1562-7. PubMed ID: 20395317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
    Barrett FS; Johnson MW; Griffiths RR
    J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment.
    Turton S; Nutt DJ; Carhart-Harris RL
    Curr Drug Abuse Rev; 2014; 7(2):117-27. PubMed ID: 25563444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.
    Johnson MW; Sewell RA; Griffiths RR
    Drug Alcohol Depend; 2012 Jun; 123(1-3):132-40. PubMed ID: 22129843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opening doors of perception: psychedelic drugs and end-of-life care.
    Macready N
    J Natl Cancer Inst; 2012 Nov; 104(21):1619-20. PubMed ID: 23104218
    [No Abstract]   [Full Text] [Related]  

  • 29. Psilocybin: Good Trip or Bad Trip.
    Sellers EM
    Clin Pharmacol Ther; 2017 Oct; 102(4):580-584. PubMed ID: 28548221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the Acute Effects of 2C-B vs. Psilocybin on Subjective Experience, Mood, and Cognition.
    Mallaroni P; Mason NL; Reckweg JT; Paci R; Ritscher S; Toennes SW; Theunissen EL; Kuypers KPC; Ramaekers JG
    Clin Pharmacol Ther; 2023 Aug; 114(2):423-433. PubMed ID: 37253161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being.
    Mason NL; Mischler E; Uthaug MV; Kuypers KPC
    J Psychoactive Drugs; 2019; 51(2):123-134. PubMed ID: 30905276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.
    Anderson T; Petranker R; Rosenbaum D; Weissman CR; Dinh-Williams LA; Hui K; Hapke E; Farb NAS
    Psychopharmacology (Berl); 2019 Feb; 236(2):731-740. PubMed ID: 30604183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dual klepsydra model of internal time representation and time reproduction.
    Wackermann J; Ehm W
    J Theor Biol; 2006 Apr; 239(4):482-93. PubMed ID: 16202427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. II. The effects of some hallucinogens on aggressiveness of mice and rats.
    Kostowski W; Rewerski W; Piechocki T
    Pharmacology; 1972; 7(4):259-63. PubMed ID: 4672886
    [No Abstract]   [Full Text] [Related]  

  • 35. Duration reproduction: lossy integration and effects of sensory modalities, cognitive functioning, age, and sex.
    Pütz P; Wittmann M; Wackermann J
    Percept Mot Skills; 2012 Oct; 115(2):370-84. PubMed ID: 23265003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psilocybin for treating substance use disorders?
    de Veen BT; Schellekens AF; Verheij MM; Homberg JR
    Expert Rev Neurother; 2017 Feb; 17(2):203-212. PubMed ID: 27684102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-dependent effects of cannabis on the neural correlates of error monitoring in frequent cannabis users.
    Kowal MA; van Steenbergen H; Colzato LS; Hazekamp A; van der Wee NJ; Manai M; Durieux J; Hommel B
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):1943-53. PubMed ID: 26298832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What Psilocybin Taught Me About Dying.
    Back AL
    J Palliat Med; 2019 Jul; 22(7):861-862. PubMed ID: 30412005
    [No Abstract]   [Full Text] [Related]  

  • 39. Differential effects of MDMA and methylphenidate on social cognition.
    Schmid Y; Hysek CM; Simmler LD; Crockett MJ; Quednow BB; Liechti ME
    J Psychopharmacol; 2014 Sep; 28(9):847-56. PubMed ID: 25052243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methodological issues of human experimental research with hallucinogens.
    Gouzoulis-Mayfrank E; Schneider F; Friedrich J; Spitzer M; Thelen B; Sass H
    Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():114-8. PubMed ID: 9754843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.